Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 May 1;54(1):35–41. doi: 10.1097/QAI.0b013e3181cf9979

Figure 2.

Figure 2

Risk of mother-to-child transmission (infant HIV DNA positive at 4-6 weeks) among women receiving HAART before or during pregnancy compared to those receiving single-dose nevirapine or no maternal prophylaxis at the Charlotte Maxeke Johannesburg Academic Hospital and Rahima Moosa Mother and Child Hospital.

* all women receiving single dose nevirapine had CD4 counts ≥ 250 cells/mm3